Clinical parameter | N = 21 |
---|---|
Age, years, median (range) | 60 (33–75) |
Gender | |
Male, n (%) | 7 (33) |
Female, n (%) | 14 (67) |
Tumor origin | |
Colon, n (%) | 19 (90) |
Rectum, n (%) | 2 (10) |
Primary in place, n (%) | 13 (62) |
Extrahepatic disease, n (%) | 14 (67) |
Extrahepatic disease sites | |
Lungs | 8 |
Lymph nodes | 5 |
Peritoneum | 1 |
Adrenal gland | 1 |
Prior systemic therapy | |
5-FU, oxaliplatin, irinotecan, and bevacizumab | 21 (100%) |
EGFR inhibitor | 9 (43) |
Regorafenib | 4 (19) |
ECOG PS | |
0 / 1 | 6 / 15 |
Liver replacement, n (%) | |
< 25% | 10 (48) |
26–50% | 11 (52) |